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Multiple sclerosis (MS) is a chronic neurodegenerative disease character-
ized by demyelination, inflammation and neurodegeneration throughout 
the central nervous system. Although spinal cord pathology is an important 
factor contributing to disease progression, few studies have examined MS 
lesions in the spinal cord and how they differ from brain lesions. In this 
study we have compared brain and spinal cord white (WM) and grey 
(GM) matter from MS and control tissues, focusing on small heat shock 
proteins (HSPB) and HSP16.2. Western blotting was used to examine 
protein levels of HSPB1, HSPB5, HSPB6, HSPB8 and HSP16.2 in brain 
and spinal cord from MS and age-matched non-neurological controls. 
Immunohistochemistry was used to examine expression of the HSPs in 
MS spinal cord lesions and controls. Expression levels were quantified 
using ImageJ. Western blotting revealed significantly higher levels of 
HSPB1, HSPB6 and HSPB8 in MS and control spinal cord compared to 
brain tissues. No differences in HSPB5 and HSP16.2 protein levels were 
observed, although HSPB5 protein levels were higher in brain WM versus 
GM. In MS spinal cord lesions, increased HSPB1 and HSPB5 expression 
was observed in astrocytes, and increased neuronal expression of HSP16.2 
was observed in normal-appearing GM and type 1 GM lesions. The high 
constitutive expression of several HSPBs in spinal cord and increased 
expression of HSPBs and HSP16.2 in MS illustrate differences between 
brain and spinal cord in health and upon demyelination. Regional differ-
ences in HSP expression may reflect differences in astrocyte cytoskeleton 
composition and influence inflammation, possibly affecting the effectiveness 
of pharmacological agents.
Keywords: alpha-B crystallin, HSP16.2, HSPBs, HSPB1, HSPB5, HSPB6, 
HSPB8, HSPB11, multiple sclerosis, pathology, spinal cord
Introduction
Multiple sclerosis (MS) is a demyelinating disease of the 
central nervous system (CNS), characterized by the devel-
opment of focal inflammatory lesions in the brain, optic 
nerve and spinal cord [1]. Previous investigations into 
regional heterogeneity have highlighted differences in 
microglia [2] and astrocyte [3] origins, morphology and 
function as well as blood–brain barrier permeability [4] 
and inflammation [5] within the CNS. The high local 
diversity suggests that well-studied disease mechanisms 
in MS-affected brains may not be directly translatable to 
other areas of the CNS. For example, treatment of trau-
matic injury with cyclosporin A reduces cortical damage 
in the brain [6], but not the spinal cord of rats [7], 
demonstrating that CNS areas react differently to phar-
macological agents. Using magnetic resonance imaging 
(MRI), the spinal cord has been shown to be affected in 
approximately 85% of MS patients by lesion development 
and/or generalized atrophy [8]. Spinal cord lesions influ-
ence functional connectivity as visualized by MRI [9], 
probably contributing to the development of lower body 
symptoms, such as walking difficulties, bladder problems 
Clinical and Experimental Immunology ORIGINAL ARTICLE  doi: 10.1111/cei.13186
R. P. Gorter et al.
138 © 2018 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for 
Immunology, Clinical and Experimental Immunology, 194:137–152
and erectile dysfunction, which severely impact upon 
quality of life in people with MS [10,11]. Conversely, 
while spinal cord involvement in MS has high clinical 
relevance, few studies have investigated spinal cord lesions 
and fewer studies have compared spinal cord and brain 
pathology directly.
The comparative pathology studies demonstrate that, 
similar to the brain, MS spinal cord is affected by focal 
demyelination in white and grey matter, microglial pro-
liferation, macrophage and T cell infiltration, astrogliosis, 
axon degeneration and neuronal loss [11‒16]. In MS spinal 
cord, the extent of white as well as grey matter demy-
elination is high compared to brain regions [17]. Relative 
to the brain, the spinal cord in MS contains few (chronic) 
active inflammatory lesions, but relatively more inactive 
and remyelinated lesions, suggesting that spinal cord MS 
pathology is less severe than the brain [11,18,19]. However, 
unlike in the brain, incomplete remyelination in the spinal 
cord correlates with clinical disability [11]. Additionally, 
in-vitro studies examining traumatic spinal cord injury 
have shown that similar mechanical insults elicit a sig-
nificantly stronger inflammatory reaction in the spinal 
cord compared to the brain, characterized by more exten-
sive lymphocyte recruitment, microglia and macrophage 
activation, astrogliosis and blood–spinal cord barrier 
breakdown [20,21].
In response to stressors such as inflammation and oxy-
gen radicals, cells up-regulate their basal expression of 
heat shock proteins (HSPs) to promote survival by pre-
venting protein aggregation and by promoting degradation 
of improperly folded proteins [22]. HSPs can be classified 
into several families, including the small heat shock pro-
teins (HSPB1-10), which serve crucial functions in neu-
roinflammation through their actions as molecular 
chaperones, cytoskeleton stabilizers and signalling mole-
cules [23]. Compared to normal-appearing white matter 
(NAWM), expression of a number of HSPBs is increased 
in oligodendrocytes and reactive astrocytes in brain white 
matter (WM) lesions [24,25], but although cell popula-
tions and tissue responses are markedly different in the 
spinal cord, it was previously unclear whether spinal cord 
cells differentially express HSPBs during MS lesion 
formation.
In this study, we compared expression levels of HSPB1, 
HSPB5, HSPB6, HSPB8 and the orphan small heat shock 
protein HSP16.2 in WM and grey matter (GM) of spinal 
cord and brain and evaluated expression of these HSPs 
during MS lesion development. We show that in spinal 
cord MS lesions, HSPBs are predominantly up-regulated 
in astrocytes, similar to the brain, but that expression 
levels of several HSPBs is markedly higher in the spinal 
cord and subtly different during lesion formation.
Materials and methods
Spinal cord tissue
Spinal cord of 24 MS cases and 13 non-neurological con-
trols (Table 1) was collected post-mortem in the pathology 
department of the VU Medical Centre (VUMC), the 
Netherlands, with the approval of the VUMC Medical 
Ethical Committee Samples according to the protocol of 
the Netherlands Brain Bank (coordinator Dr I. Huitinga, 
Amsterdam, the Netherlands). Tissues were fresh-frozen 
or fixed in formalin and embedded in paraffin. Participants 
had given informed consent for autopsy and use of mate-
rials for research.
Western blotting
GM and WM from eight age-matched non-neurological 
controls [mean age  =  71·5 years (62·3–80·7)] and eight 
MS patients [mean age  =  71·5 years (63·3–79·7)] was 
obtained from fresh-frozen blocks containing control white 
matter (CWM) and/or control grey matter (CGM) or 
NAWM and/or normal-appearing grey matter (NAGM). 
For spinal cord, GM and WM were separated manually. 
Samples were homogenized in TNE buffer [50  mM Tris-
HCl, 150  mM M NaCl and 5  mM ethylenediamine 
tetraacetic acid (EDTA), pH 7·5]. Total protein concentra-
tion was measured using Bio-Rad DC Protein Assay (Bio-
Rad Laboratories, Hercules, CA, USA) with bovine serum 
albumin (BSA) as standard. Equal amounts of protein 
(50  μg) and sodium dodecyl sulphate (SDS) reducing 
loading buffer were mixed and samples were denatured 
at 95ºC for 5  min. Proteins were separated by 15% SDS-
polyacrylamide gel electrophoresis (PAGE) and transferred 
to immobilon-FL transfer membrane (Merck Millipore, 
Burlington, MA, USA) using a semidry blotting system. 
After three washes with phosphate-buffered saline (PBS), 
membranes were blocked in Odyssey blocking buffer for 
1  h (1  :  1 with PBS; Li-Cor Biosciences, Lincoln, NE, 
USA), followed by incubation with primary antibodies 
(Table 2) overnight at 4°C. After washing with PBS con-
taining 0·05% Tween-20, membranes were incubated with 
the appropriate IRDye®-conjugated secondary antibodies 
(1  :  3000; Li-Cor Biosciences). Membranes were scanned 
with Odyssey version 3.0 analysis software. Subsequently, 
Scion Image software was used to analyse intensity. Actin 
was used as a loading control.
Statistical analysis
To compare HSPB expression in MS and controls, WM 
and GM and brain and spinal cord, values from each 
blot were normalized to a reference sample. Data were 
tested for normality and equality of variances using 
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Bartlett’s test and the Brown–Forsythe test. Accordingly, 
analysis of variance (anova) or Kruskal–Wallis test was 
performed. When significant differences were found, 
Sidak’s or Dunn’s multiple comparisons test were used 
for post-hoc testing. When HSP levels showed high indi-
vidual variability, data were expressed as relative values 
(brain WM  =  1) to compare differences in HSPB expres-
sion between WM and GM as well as spinal cord and 
brain. Data were tested for normality using the 
Kolmogorov–Smirnov normality test. To compare expres-
sion to brain WM, one-sample t-test or Wilcoxon’s signed-
rank test was used. To compare between other groups, 
Table 1. Patient characteristics 
Case Gender Age (years) DD (years) MS type PMD (h:m) Cause of death Tissue
Fresh-frozen tissue
MS patients
1 M 63 24 PP 7:05 Cardiac arrest; ruptured abdominal aorta 
aneurysm
B, T
2 M 71 25 PP/SP 7:00 Pneumonia by aspiration B, T
3 M 56 14 PP 9:50 Cachexia; exhaustion; terminal phase MS B, T
4 M 83 21 PP 7:50 Aspiration pneumonia; lung cancer B, T
5 F 66 16 SP 10:45 Pulmonary hypertension B, T
6 F 81 27 SP 4:35 Aspiration pneumonia B, T
7 M 70 47 PP 6:55 Acute heart failure; Clostridium difficile colitis B, T
8 F 82 60 SP 8:35 Euthanasia B, T
Controls
1 M 71 n.a. CON 7:40 Sepsis B, T
2 F 61 n.a. CON 6:50 Euthanasia B, L
3 M 62 n.a. CON 7:20 Unknown B, unkn.
4 F 78 n.a. CON 7:10 Euthanasia B, T
5 F 60 n.a. CON 8:10 Metastasized mammary carcinoma B, L
6 M 93 n.a. CON 7:40 Heart failure B, T
7 F 72 n.a. CON 6:50 Euthanasia; metastasized ovarian cancer; ileus B, L
8 F 75 n.a. CON 9:10 Euthanasia B, T
Paraffin-embedded tissue
MS patients
2 M 71 25 PP/SP 7:00 Pneumonia by aspiration T
5 F 66 16 SP 10:45 Pulmonary hypertension T
6 F 81 27 SP 4:35 Aspiration pneumonia C, L
9 M 64 34 SP 7:30 Terminal phase MS; spastic MS T
10 F 84 34 PP <0:01 Euthanasia unkn.
11 F 44 5 PP 10:15 Decompensation T
12 M 56 21 SP 8:00 Pneumonia T
13 F 69 53 PP/SP 7:30 Respiratory failure; heart failure T
14 M 47 6 PP/SP 7:15 Urosepsis; organ failure T
15 M 61 18 SP 9:15 Euthanasia T
16 F 77 24 PP 10:00 Euthanasia T
17 F 67 25 SP 9:15 Palliative sedation; shortness of breath T
18 M 44 21 PP 10:15 Possible infection due to terminal phase MS T
19 F 76 25 SP 7:55 Euthanasia; lung cancer with brain metastases T
20 M 54 12 PP 8:15 Euthanasia T
21 F 50 17 SP 7:35 Euthanasia T
22 F 54 31 PP/SP 9:20 Heart failure T
23 M 58 18 SP 9:15 Pneumonia; terminal renal insufficiency T
24 M 63 25 SP 8:15 Pneumonia; cachexia; dehydration C
Controls
2 F 61 n.a. CON 6:50 Euthanasia unkn.
9 M 67 n.a. CON 4:30 Cardiac shock; multiple organ failure unkn.
10 M 81 n.a. CON 5:30 Metastasized prostate carcinoma unkn.
11 F 91 n.a. CON 7:45 Decompensatio cordis unkn.
12 M 67 n.a. CON 18:35 Myocardial infarction C
13 F 84 n.a. CON 4:45 Respiratory failure T
PM = post mortem; M = male; F = female; CON = control; MS = multiple sclerosis; SP = secondary progressive; PP = primary progressive; n.a. = not 
applicable; m = months; B = brain; C = cervical; T = thoracic; L = lumbar; S = sacral; unkn. = unknown. 
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two-sided unpaired Student’s t-test or Mann–Whitney 
U-test was performed. Results were considered statistically 
significant when P  <  0·05.
Immunohistochemistry
Serial 5-µm paraffin sections were cut of spinal cord tissue 
from six non-neurological controls [mean age = 75·2 years 
(62·8–87·6)] and 19 MS patients [mean age  =  62·4 years 
(56·6–68·3)]. Sections were taken from CWM (n  =  6), 
NAWM (n  =  5), active lesions (n  =  4–5), chronic active 
lesions (n  =  4–5), inactive lesions (n = 4), CGM 
(n = 4-5), NAGM (n = 4-5), GM type I lesions (n = 8) 
and GM type II lesions (n = 4). All sections were stained 
for proteolipid protein (PLP), human leucocyte antigen 
receptor D-related (HLA-DR) and double-stained for 
HSPB1, HSPB5, HSPB6, HSPB8, HSP16.2 and HLA-DR, 
olig2 and vimentin. Sections were deparaffinized with xylene, 
rehydrated in graded ethanol solutions and washed in 
water. Endogenous peroxidase was blocked by incubating 
the slides in PBS containing 0.3% (v/v) hydrogen peroxide 
for 30  min. After washing in PBS, heat-mediated antigen 
retrieval was performed using either 0·01  M citrate buffer 
(pH 6) or EDTA buffer (pH 9). After cooling and washing 
in PBS, slides were incubated for 1  h or overnight with 
primary antibodies (Table 2) diluted in normal antibody 
diluent (Immunologic, Duiven, the Netherlands) at room 
temperature (RT). Sections were washed and incubated 
with the secondary antibody: goat anti-mouse horseradish 
peroxidase (HRP) Envision (Dako, Carpenteria, CA, USA) 
for HSPB5 and goat anti-rabbit HRP Envision (Dako) for 
other HSPBs. After washing with PBS, the staining was 
developed with 3,3-diaminobenzidine (DAB; Dako) at a 
1  :  50 concentration for 10  min. For single staining (PLP 
and HLA-DR), slides were washed in tap water and nuclei 
were counterstained with haematoxylin, dehydrated in 
ascending alcohol concentrations and xylene and mounted 
with Quick-D (Klinipath, Duiven, the Netherlands).
To identify HSPB expression in MS lesions, double-
labelling was performed for HSPBs and HLA-DR (micro-
glia). To identify other cells expressing HSPBs, 
double-labelling was performed for olig2 (oligodendro-
cytes) or vimentin (astrocytes). Sections were stained with 
HSPBs as described above, and after developing with DAB 
the slides were washed and incubated with the second 
primary antibody for 1  h or overnight (Table 2). When 
primary antibodies were from the same species, the anti-
body directed to the first antigen of choice was detached 
by heating in citrate buffer for 15  min. After washing, 
the appropriate secondary antibody, goat anti-mouse alka-
line phosphatase (AP) or goat anti-rabbit AP, was applied 
for 1  h. After washing twice with PBS and once with 
Tris-buffered saline (TBS), slides were developed with 
liquid permanent red (LPR; Dako; 1  :  100) for 10  min. 
Slides were washed in tap water and nuclei were coun-
terstained with haematoxylin, washed with tap water and 
mounted with aquatex (Merck, Darmstadt, Germany). 
Following omission of primary antibodies, no staining 
was observed.
Digital quantification
HSPB expression was analysed using ImageJ to determine 
the DAB+ pixels. For each region of interest, four to five 
pictures of HSPB/HLA-DR double-staining were taken at 
×400 magnification using an Olympus BX41 microscope 
equipped with a Leica MC170 HD camera. Thresholds 
were set to eliminate background expression. Next, using 
Table 2. Antibodies 
Antigen Antibody number Species Clone Dilution IHC/WB Incubation time Company
(a) Primary antibodies
HSPB1 AB155987 Rabbit Monoclonal 1:1500/1:1000 O/N Abcam
HSPB5 JAM01 Mouse Monoclonal 1:750/1:200 O/N In house
HSPB6 AB184161 Rabbit Monoclonal 1:50000/1:2000 O/N Abcam
HSPB8 AB96837 Rabbit Polyclonal 1:3500/1:2000 O/N Abcam
HSP16.2 NBP1-88332 Rabbit Polyclonal 1:50 O/N Novus
HLA-DR 14-99-56-82 Mouse Monoclonal 1:1000 1 h eBioscience
olig2 AB9610 Rabbit Polyclonal 1:750 O/N Millipore
Vimentin V9 Rabbit Mouse 1:128000 1 h In house
(b) Secondary antibodies
EnVision HRP anti-rabbit Goat Undiluted Dako
EnVision HRP anti-mouse Goat Undiluted Dako
Goat anti-mouse AP Goat 1:250 Dako
Goat anti-rabbit AP Goat 1:250 Southern Biotech
olig2 = oligodendrocyte transcription factor 2; HSPB = small heat shock protein; HLA-DR = human leucocyte antigen D-related; HRP = horserad-
ish peroxidase; AP = alkaline phosphatase, O/N = overnight; IHC = immunohistochemistry. 
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the macro supplied in Supporting information, 
Appendix A, brown DAB staining was separated from 
blue haematoxylin staining and pink LPR staining and 
the DAB+ area fraction was determined.
Statistical analysis
Using GraphPad Prism version 6 (GraphPad Software, 
La Jolla, CA USA; https://www.graphpad.com/scientific-
software/prism/), differences in HSPB expression in WM 
and GM lesions were examined. Data was tested for nor-
mality. Then, expression in CWM/CGM and NAWM/
NAGM was compared using Student’s t-test or Mann–
Whitney U-test. When expression in NAWM/NAGM did 
not differ from controls, other groups were compared to 
NAWM/NAGM. When expression differed, other groups 
were compared to controls. anova and Dunnett’s post-
hoc testing or Kruskal–Wallis H-test and Dunn’s post-hoc 
testing was performed (P  <  0·05).
Results
Increased HSPB1, 6, 8 protein levels in spinal cord 
compared to brain
Western blotting was used to compare protein levels of 
HSPB1, HSPB5, HSPB6, HSPB8 and HSP16.2 in fresh-
frozen brain and spinal cord blocks from MS cases and 
non-neurological controls (Table 1). Blocks were screened 
by immunostaining sections for PLP and HLA-DR to 
select regions containing CWM/CGM in controls and 
NAWM/NAGM in MS cases to exclude blocks containing 
lesions. Although increased mRNA levels of HSPB1, HSPB6 
and HSPB8 have been reported previously in MS brain 
NAWM [24], no differences in HSPB or HSP16.2 protein 
expression were found between controls and MS patients 
(Supporting information, Fig. 1). However, a marked 
increase in HSPB1 (Fig. 1a–c; P  =  0·0078; P  =  0·0409), 
HSPB6 (Fig. 1d–f; P  =  0·0111; P  =  0·0078) and HSPB8 
(Fig. 1g–i; P  =  0·0286; P  =  0·0016) protein levels was 
observed in the WM of spinal cord tissues compared to 
brain WM in controls and MS patients, respectively. 
Similarly, in spinal cord GM, HSPB1 (Fig. 1a–c; P = 0·0070; 
P = 0·0003) and HSPB6 (Fig. 1d–f; P = 0·0104; P = 0·0002) 
levels were significantly higher than in brain GM, in 
controls as well as MS patients, but no differences were 
found for HSPB8 (Fig. 1g–i; P  =  0·1506; P  =  0·2368). 
Contrastingly, HSPB5 (Fig. 1j–l) and HSP16.2 (Fig. 1m–o) 
expression did not differ between spinal cord and brain 
samples in MS patients or controls, but the variance in 
the expression levels, particularly of HSPB5, was notice-
ably greater for MS patients. HSPB5 expression was also 
significantly higher in brain WM compared to brain GM 
in controls (Fig. 1k; P  =  0·0078), but not in MS patients 
(Fig. 1l; P  =  0·1953). For HSP16.2, bands were not only 
observed at 16 kDa, which is the predicted molecular 
weight, but also approximately 40, 60, 70 and 250 kDa, 
possibly indicating the presence of HSP16.2 complexes 
(Supporting information, Fig. 2). Of note, these bands 
were present in the brain, especially in the GM, but not 
in the spinal cord.
Spinal cord lesions are classified based on 
inflammatory activity or location
Next, we evaluated expression of HSPB1, HSPB5, HSPB6, 
HSPB8 and HSP16.2 in CWM, CGM, NAWM, NAGM 
and upon lesion development in the spinal cord. WM 
lesions were classified as active, chronic active or inactive 
based on PLP staining and HLA-DR expression (Fig. 2). 
Active lesions (Fig. 2a,b) and the rim of chronic active 
lesions (Fig. 2c,d) were characterized by extensive micro-
glial activation and macrophage infiltration, while inactive 
lesions (Fig. 2e,f) were devoid of HLA-DR+ cells. As GM 
lesions feature little microglial activity, brain GM lesions 
are classified in type I to IV based on their location. The 
spinal cord differs in anatomical structure, thus we limited 
classification of spinal cord lesions to type I (mixed WM 
and GM lesions; Fig. 2g,h) and type II (pure GM lesions; 
Fig. 2I,j).
Astrocytes up-regulate HSPB1 in MS spinal cord 
lesions
Consistent with protein analysis (Fig. 1a,c), HSPB1 was 
expressed constitutively in CWM (Fig. 3a) and NAWM 
(Fig. 3b) in the cytoplasm of cells with an astrocyte-like 
morphology. In MS lesions, HSPB1 expression was 
observed in cells with an astrocyte morphology (Fig 3c–g). 
Such expression was increased significantly in the rim of 
chronic active lesions (Fig. 3; P  =  0·0474) and in inactive 
lesions (Fig. 3f,g; P  =  0·0369) in vimentin+ astrocytes 
(insert Fig. 3). In the centre of chronic active lesions, a 
trend towards increased HSPB1 expression was seen (Fig. 
3e,g; P  =  0·0895). In CGM (Fig. 3i) and NAGM (Fig. 
3j), HSPB1 expression was observed sparsely in the soma 
and axons of neurones and occasionally in astrocytes 
(insert in k), but was not changed significantly in GM 
lesions (Fig. 3h,k,l).
HSPB5 expression is increased in active lesions and the 
rim of chronic active lesions
In CWM (Fig. 4a), sparse HSPB5 expression was observed 
in cells with an astrocyte-like morphology and in oligo-
dendrocyte (progenitor cells), as confirmed with oligo-
dendrocyte lineage marker Olig2 (insert Fig. 4a). In 
comparison, a slight, but statistically significant, increase 
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Fig. 1. Heat shock protein (HSP) levels in brain and spinal cord. Heat shock protein B (HSPB) 1, HSPB5, HSPB6, heat shock protein B (HSPB)8 and 
HSP16.2 protein levels in brain white matter/grey matter (WM/GM) and spinal cord WM/GM of controls (n = 8) and multiple sclerosis (MS) patients 
(n = 8) were determined using Western blotting and quantified with Scion Image. Representative blots are shown (top to bottom: HSP controls, actin 
controls, HSP MS patients, actin MS patients). Actin was used as a loading control. Values are expressed as ratio of brain WM (BWM  = 1). (a) Western 
blot featuring HSPB1 protein levels. (b) Quantification HSPB1 protein levels controls. (c) Quantification HSPB1 protein levels MS patients. 
(D) Western blot featuring HSPB6 protein levels. (e) Quantification HSPB6 protein levels controls. (f) Quantification HSPB6 protein levels MS patients. 
(g) Western blot featuring HSPB8 protein levels. (h) Quantification HSPB8 protein levels controls. (i) Quantification HSPB8 protein levels MS patients. 
(j) Western blot featuring HSPB5 protein levels. (k) Quantification HSPB5 protein levels controls. (l) Quantification HSPB5 protein levels MS patients. 
(m) Western blot featuring HSP16.2 protein levels. (n) Quantification HSP16.2 protein levels controls. (o) Quantification HSP16.2 protein levels MS 
patients. To compare expression in brain and spinal cord WM, one-sample t-test or Wilcoxon’s signed rank test was used. Significant data are presented 
(####P < 0·0001, ###P < 0·001, ##P < 0·01, #P < 0·05). To compare expression between other groups, unpaired Student’s t-test or Mann–Whitney U-test 
was performed. Data are presented as mean with standard error of the mean. Significant data are presented (****P < 0·0001, ***P < 0·001, **P < 0·01, 
*P < 0·05).
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Fig. 2. White (WM) and grey matter (GM) spinal cord lesions. WM lesions were staged as active, chronic active or inactive based on the presence of 
demyelination and (foamy) microglia and/or macrophages as visualized by proteolipid protein (PLP) and human leucocyte antigen D-related (HLA-
DR) staining. GM lesions were staged as type I and type II lesions based on WM/GM involvement. (a) Active lesion PLP staining. (b) Active lesion 
HLA-DR staining with a close-up of foamy microglia and/or macrophages. (c) Chronic active lesion PLP staining. (d) Chronic active lesion HLA-DR 
staining. (e) Inactive lesion PLP staining. (f) Inactive lesion HLA-DR staining. (g) Type I GM lesion PLP staining. (h) Type I GM lesion HLA-DR 
staining. (i) Type II GM lesion PLP staining. (j) Type II GM lesion HLA-DR staining with a close-up of a neurone surrounded by HLA-DR+ microglia 
and/or macrophages. Where applicable, the borders between WM and GM are delineated with a dotted line. Scale bar in all pictures is 50 µm. Inserts 
are digitally enlarged. 
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in expression was observed in MS NAWM (Fig. 4b,g; 
P  =  0·0173), although this was not reflected in the WB 
studies where HSPB5 expression did not differ between 
brain and spinal cord CWM and NAWM. Relative to 
CWM, expression of HSPB5 was also increased signifi-
cantly in active lesions (Fig. 4c,g; P  =  0·0005) and in the 
rim of chronic active lesions (Fig. 4d,g; P  =  0·0169), 
mainly in vimentin+ astrocytes (insert Fig. 4c). Conversely, 
HSPB5 expression was not increased significantly in the 
centre of chronic active lesions (Fig. 4; P  =  0·2581) or 
in inactive lesions (Fig. 4f,g; P  =  0·7581), although here 
HSPB5+vimentin+ astrocytes were observed occasionally 
(insert Fig. 4e). While HSPB5 expression was observed 
in WM astrocytes, HSPB5 was not observed in GM astro-
cytes, with the exception of astrocytes in the immediate 
proximity of the central canal (data not shown). In CGM 
(Fig. 4h,i) and NAGM (Fig. 4h,j), oligodendrocyte lineage 
cells expressed HSPB5, while in demyelinated GM lesions 
(Fig. 4,k,l), HSPB5+olig2+ oligodendrocytes were observed 
rarely (data not shown). Neuronal expression of HSPB5 
was not observed.
Morphologically distinct astrocytes express 
differentially phosphorylated HSPB5
Phosphorylation of HSPB5 at serine 59 (ser59) has been 
implicated recently in astrogliosis [26] prompting the 
evaluation of the different phosphorylated forms of HSPB5: 
serine 19 (ser19), serine 45 (ser45) and ser59 in the 
spinal cord (Fig. 4m,p). In CWM and CGM, cells with 
an oligodendrocyte-like morphology expressed all three 
variants of HSPB5, most prominently ser59 close to the 
nucleus, while only few ser19/45/59+ cells with an 
Fig. 3. Heat shock protein B (HSPB)1 expression in multiple sclerosis (MS) spinal cord lesions. Using immunohistochemistry (IHC), HSPB1 expression 
was evaluated in control white matter (CWM) (n  = 6), normal-appearing white matter (NAWM) (n = 5), active lesions (n = 4), chronic active lesions 
(n = 5), inactive lesions (n = 4), control grey matter (CGM) (n = 4), normal-appearing grey matter (NAGM) (n = 4), type I GM lesions (n = 8) and type 
II GM lesions (n = 4). Representative lesions, stained for HSPB1 (brown) and human leucocyte antigen D-related (HLA-DR) (pink), are shown. HSPB1 
expression was quantified by determining HSPB1+ pixels using ImageJ. (a) HSPB1 expression in CWM. (b) HSPB1 expression in NAWM. (c) HSPB1 
expression in an active lesion with a close-up of an HSPB1+ (brown) cell with an astrocyte-like morphology. (d) HSPB1 expression in the rim of a 
chronic active lesion with an insert of a HSPB1+ (brown) vimentin+ (pink) astrocyte. (e) HSPB1 expression in the centre of a chronic active lesion. (f) 
HSPB1 expression in an inactive lesion. (g) Quantification HSPB1+ pixels in WM lesions. (h) Quantification of HSPB1+ pixels in GM lesions. (i) HSPB1 
expression in CGM. (j) HSPB1 expression in NAGM with an insert of a HSPB1+ neurone. (k) HSPB1 expression in WM and GM of a type I GM lesion 
with a close-up of a HSPB1+ (brown) cell with an astrocyte-like morphology. (l) HSPB1 expression in a type II GM lesion. Statistically significant 
differences were evaluated by first comparing CWM/CGM and NAWM/NAGM with Student’s t-test or Mann–Whitney U-test. No significant 
differences were found and NAWM/NAGM was next used to compare whether HSPB1 expression was up-regulated in GM/WM lesions using analysis 
of variance (anova) and Dunnett’s post-hoc test or Kruskal–Wallis test and Dunn’s post-hoc test. Data are presented as mean with standard error of the 
mean. Significant data are presented (****P < 0·0001, ***P < 0·001, **P < 0·01, *P < 0·05). Scale bar in all pictures is 50 µm. Inserts are digitally enlarged. 
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Fig. 4. Heat shock protein B (HSPB)5 expression in spinal cord lesions. Using immunohistochemistry (IHC), HSPB5 expression and expression of the 
different phosphorylated forms of HSPB5 (ser19, ser45, ser59) were evaluated in control white matter (CWM) (n = 6), normal-appearing white matter 
(NAWM) (n = 5), active lesions (n = 4), chronic active lesions (n = 4), inactive lesions (n = 4), control grey matter (CGM) (n = 5), normal-appearing 
grey matter (NAGM) (n = 4), type I GM lesions (n = 8) and type II GM lesions (n = 4). HSPB5 expression was quantified by determining HSPB5+ pixels 
using ImageJ. Representative pictures stained for ser19/ser45/ser59 (brown) and human leucocyte antigen D-related (HLA-DR) (pink) are shown. (a) 
HSPB5 expression in CWM with an insert of HSPB5+ (brown) olig2+ (pink) oligodendrocytes. (b) HSPB5 expression in NAWM with a close-up of a 
HSPB5+ (brown) cell with an astrocyte-like morphology. (c) HSPB5 expression in an active lesion with an insert of an HSPB5+ (brown) vimentin+ 
(pink) astrocyte. (d) HSPB5 expression in the rim of a chronic active lesion with a close-up of a HSPB5+ (brown) cell with an astrocyte-like morphology. 
(e) HSPB5 expression in the centre of a chronic active lesion with a close-up of an HSPB5+ (brown) cell with an astrocyte-like morphology. (f) HSPB5 
expression in an inactive lesion with a close-up of an HSPB5+ (brown) cell with an astrocyte-like morphology. (g) Quantification HSPB5+ pixels in WM 
lesions. (h) Quantification HSPB5+ pixels in GM lesions. (i) HSPB5 expression in CGM with an insert of HSPB5+ (brown) olig2+ (pink) oligodendrocytes. 
(j) HSPB5 expression in NAGM with a close-up (insert) of a neuron and a HSPB5+ (brown) cell that morphologically resembles an oligodendrocyte 
(arrow). (k) HSPB5 expression in WM and GM of a type I GM lesion. (l) HSPB5 expression in a type II GM lesion. (m) Ser19 expression in an active 
lesion with a close-up of a ser19+ cell with an astrocyte-like morphology. (n) Ser45 expression in an active lesion with a close-up of a ser45+ cell with an 
astrocyte-like morphology. (o) Ser59 expression in an active lesion with a close-up of a ser59+ cell with an astrocyte-like morphology. (p) Ser19 
expression in the rim of a chronic active lesion with a close-up of a ser19+ cell with an astrocyte-like morphology. (q) Ser59 expression in the rim of a 
chronic active lesion. (r) Ser59 expression in the centre of a chronic active lesion. (s) Ser59 expression in an inactive lesion. Statistically significant 
differences were evaluated by first comparing CWM/CGM and NAWM/NAGM with Student’s t-test or Mann–Whitney U-test. If significant differences 
were found, NAWM/NAGM, and otherwise CWM/CGM, was next used to compare whether HSPB5 expression was up-regulated in GM/WM lesions 
using analysis of variance (anova) and Dunnett’s post-hoc test or Kruskal–Wallis test and Dunn’s post-hoc test. Data are presented as mean with 
standard error of the mean. Significant data are presented (****P < 0·0001, ***P < 0·001, **P < 0·01, *P < 0·05). Scale bar in all pictures is 50 µm. Inserts 
are digitally enlarged.
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astrocyte-like morphology were observed (data not 
shown). In active lesions, ser19 expression (Fig. 4m), 
and occasionally ser45 expression (Fig. 4n), were observed 
in the soma of cells with an astrocyte-like appearance 
and a hypertrophic morphology, while ser59 (Fig. 4o) 
was up-regulated highly in the cell body and processes 
of astrocyte-like cells with a ramified appearance. In the 
rim of chronic active lesions, low ser19 expression (Fig. 
4p) and high ser59 expression (Fig. 4q) was observed, 
while in the centre of chronic active lesions (Fig. 4r) 
and in inactive lesions (Fig. 4s), only ser59 was found 
occasionally in ramified astrocytes. In active lesions and 
the rim of chronic active lesions all three variants were 
also detected in foamy macrophages in blood vessels 
(data not shown).
Expression of HSPB6 and HSPB8 is not altered in 
spinal cord lesions
HSPB6 (Fig. 5a,b) and HSPB8 (Fig. 5I,j) expression was 
observed in astrocyte-like cells in CWM and NAWM. 
Although several active lesions (Fig. 5d) and chronic active 
lesions (data not shown) revealed HSPB6 expression in 
astrocytes, as confirmed by double-staining with vimentin 
(insert Fig. 5c), HSPB6 expression in MS lesions was not 
significantly different from NAWM (Fig. 5d). Similarly, 
HSPB8 expression was detected in HSPB8+vimentin+ astro-
cytes (insert Fig. 5k) in three of four inactive lesions 
(Fig. 5k), but no significant differences were detected (Fig. 
5k; P  =  0·2853). Expression of HSPB6 and HSPB8 was 
not observed in oligodendrocyte lineage cells (data not 
shown). In CGM and NAGM, expression of HSPB6 (Fig. 
5e,f) and HSPB8 (Fig. 5m,n) was observed in GM astro-
cytes. No changes in HSPB6 and HSPB8 expression were 
observed in type I (Fig. 5g,h,o,p) or in type II GM lesions 
(data not shown).
HSP16.2 expression is increased in NAGM and type I 
GM lesions
HSP16.2 expression was observed in cells with an astro-
cyte-like morphology in CWM (Fig. 5q), NAWM (Fig. 
5r) and MS lesions (Fig. 5s,t). In active lesions (Fig. 
5s,t; P  =  0·8781), HSP16.2+vimentin+ astrocytes were 
present (insert, Fig. 5s), although HSP16.2 expression 
was not significantly different from NAWM. While 
HSP16.2 expression was observed only occasionally in 
GM astrocytes, neurones throughout the GM expressed 
HSP16.2 in a synaptic pattern in CGM (Fig. 5u), NAGM 
(Fig. 5v) and GM lesions (Fig. 5w,x). Compared to CGM, 
HSP16.2 expression was significantly higher in NAGM 
(Fig. 5v,x; P  =  0·0244) and type I GM lesions (Fig. 
5w,x; P  =  0·0329), although no differences were detected 
with WB.
Discussion
Spinal cord pathology is a crucial factor contributing to 
disease progression in MS. Although there is high regional 
heterogeneity in the CNS, possibly influencing local 
responses to pharmacological agents, pathology studies 
focus frequently on brain pathology, neglecting the clinical 
relevance of MS lesions arising outside the brain. in this 
study, we compared HSPBs and HSP16.2 levels in brain 
and spinal cord WM and GM, and further investigated 
HSP expression in WM and GM spinal cord lesions. We 
show that in the spinal cord, similar to the brain, astro-
cytes are the main source of HSPBs, but that basal levels 
of HSPB1, HSPB6 and HSPB8 are increased markedly in 
the spinal cord, more prominently in WM, and that 
expression of HSPB5 and HSP16.2 in spinal cord lesions 
is subtly different from the brain.
Using WB and IHC, our studies reveal that spinal cord 
astrocytes have higher basal expression of HSPB1, HSPB6 
and HSPB8 than brain astrocytes. Throughout the CNS, 
astrocytes perform a wide variety of functions, including 
facilitation of neuronal/axonal growth, clearing waste 
products, regulation of glutamate transport, controlling 
blood–brain barrier integrity and enabling scar formation 
in reaction to tissue injury [3,27]. Regional astrocyte sub-
sets are specialized morphologically, molecularly and 
functionally to optimally function in their microenviron-
ment [28,29]. A recent study showed that levels of glial 
fibrillary acid protein (GFAP) are higher in both in WM 
and GM in murine spinal cord compared to brain, and 
increased in cultured spinal cord astrocytes compared to 
cortical astrocytes [30]. GFAP is the principal intermediate 
filament cytoskeletal protein in adult astrocytes, important 
in providing cell shape, strength and motility [31]. Increased 
levels of GFAP (and possibly other cytoskeletal proteins) 
in spinal cord astrocytes may be advantageous as, due 
to anatomical localization and increased mobility, the 
spinal cord is subjected to far greater mechanical stress 
than the brain. HSPBs interact with the cytoskeleton by 
preventing aggregation, influencing assembly and provid-
ing stabilization of cytoskeletal proteins, such as GFAP 
[32]. The relatively high levels of HSPB1, HSPB6 and 
HSPB8 in WM (and GM) spinal cord astrocytes as we 
show here are probably necessary for proper functioning 
of the cytoskeleton. HSPB1 associates with GFAP under 
non-stressed conditions and upon heat shock, inhibiting 
GFAP assembly [33]. To our knowledge, HSPB6 and 
HSPB8 are not known to interact with GFAP, although 
both HSPs are involved in assembly/disassembly dynamics 
of the microfilament actin [34,35], another astrocyte 
cytoskeletal protein [36]. Of note, HSPB5 (and HSP16.2) 
expression was not more abundant in spinal cord, 
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Fig. 5. Heat shock protein B (HSPB)6, HSPB8 and HSP16.2 expression in multiple sclerosis (MS) spinal cord lesions. Using immunohistochemistry (IHC), 
HSPB6, HSPB8 and HSP16.2 expression was evaluated in control white matter (CWM) (n = 6), normal-appearing white matter (NAWM) (n = 5), active 
lesions (n = 5), chronic active lesions (n = 5), inactive lesions (n = 4), CGM (n = 4–5), NAGM (n = 4), type I GM lesions (n = 8) and type II GM lesions (n = 4). 
Representative lesions, stained for HSPB6/HSPB8/HSP16.2 (brown) and human leucocyte antigen D-related (HLA-DR) (pink), are shown. HSPB6/HSPB8/
HSP16.2 expression was quantified by determining HSP+ pixels using ImageJ. (a) HSPB6 expression in CWM. (b) HSPB6 expression in NAWM. (c) HSPB6 
expression in an active lesion with an insert of an HSPB6+ (brown) vimentin+ (pink) astrocyte. (d) Quantification of HSPB6+ pixels in WM lesions. (e) 
HSPB6 expression in control grey matter (CGM). (f) HSPB6 expression in normal-appearing grey matter (NAGM. (g) HSPB6 expression in WM and GM 
of a type I GM lesion. (h) Quantification HSPB6+ pixels in GM lesions. (i) HSPB8 expression in CWM. (j) HSPB8 expression in NAWM. (k) HSPB8 
expression in an inactive lesion with an insert of a HSPB8+ (brown) vimentin+ (pink) astrocyte. (l) Quantification of HSPB8+ pixels in WM lesions. (m) 
HSPB8 expression CGM. (n) HSPB8 expression in NAGM. (o) HSPB8 expression in WM and GM of a type I GM lesion. (p) Quantification of HSPB8+ pixels 
in GM lesions. (q) HSP16.2 expression in CWM. (r) HSP16.2 expression in NAWM. (s) HSP16.2 expression in an active lesion with an insert of a HSP16.2+ 
(brown) vimentin+ (pink) astrocyte. (t) Quantification of HSP16.2+ pixels in WM lesions. (u) HSP16.2 expression in CGM. (v) HSP16.2 expression in 
NAGM. (w) HSP16.2 expression in WM and GM of a type I GM lesion. (x) Quantification of HSP16.2 expression in GM lesions. Statistically significant 
differences were evaluated by first comparing CWM/CGM and NAWM/NAGM with Student’s t-test or Mann–Whitney U-test. If no significant differences 
were found, NAWM/NAGM, and otherwise CWM/CGM, was next used to compare whether HSP expression was up-regulated in GM/WM lesions using 
analysis of variance (ANOVA) and Dunnett’s post-hoc test or Kruskal–Wallis test and Dunn’s post-hoc test. Data are presented as mean with standard error 
of the mean. Significant data are presented (****P < 0·0001, ***P < 0·001, **P < 0·01, *P < 0·05). Scale bar in all pictures is 50 µm. Inserts are digitally enlarged. 
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underscoring the concept that HSPBs are structurally 
related, but functionally highly heterogeneous [37]. HSPB5 
is well known to bind to GFAP, inhibiting GFAP fibril 
formation in vitro [38] and in vivo [39], raising the ques-
tion of why HSPB5 levels are not up-regulated. As HSPB1, 
HSPB6 and HSPB8 are involved in many cellular processes 
besides cytoskeleton maintenance, including proteostasis, 
cell division and protection against oxidative radicals [37], 
increased spinal cord levels of these HSPBs may not (only) 
signify cytoskeletal heterogeneity, but reflect other differ-
ences between the spinal cord and the brain, such as 
greater remyelinating capacity [19], relatively higher per-
meability of the blood–spinal cord barrier [4], mitochon-
drial differences [40,41], higher metabolic requirements 
or increased cell turnover.
MS spinal cord lesions are markedly different from 
previous studies in brain lesions [24] with regard to 
HSP16.2 and HSPB5 expression, illustrating that the spinal 
cord and brain do not only differ in healthy conditions, 
but also in their reactions to tissue injury. A previous 
study by our group evaluated (small) HSP expression 
upon MS lesion development in the brain and reported 
increased expression of HSPB1, HSPB6 and HSPB8 in 
MS lesions, mainly in the centre of chronic active lesions 
[24]. Although in the spinal cord only HSPB1 expression 
was significantly different in the rim of chronic active 
lesions and inactive lesions, the disparity might be due 
partly to study design. First, the study in MS brain quan-
tified HSP expression relative to the total number of cells 
[24], thus underestimating HSP levels per cell as well as 
HSP levels in active lesions and the rim of chronic active 
lesions in case large numbers of microglia and macrophages 
are present which do not express HSPs. Secondly, the 
statistical power of the current study is limited by the 
availability of spinal cord tissues.
Contrary to the investigated HSPBs, which are expressed 
mainly by astrocytes (and HSPB5 by oligodendrocyte line-
age cells), HSP16.2 expression was found to be most 
prominent in spinal cord neurones, where it was expressed 
in the cytosol and on the neuronal membrane in a syn-
aptic pattern in CGM, NAGM and GM lesions. 
Quantification of IHC found that neuronal HSP16.2 expres-
sion was significantly more intense in NAGM and type 
I GM lesions compared to CGM, unlike that seen previ-
ously in cortical lesions, where no differences in HSP16.2 
expression were found [24]. However, while no differences 
were detected in HSP16.2 levels between MS patients and 
controls using WB, complexes of HSP16.2 were observed 
in the brain GM but not the spinal cord. Alternatively, 
differences observed using IHC, but not WB, might be 
due to age differences, as for the IHC study MS patients 
with spinal cord lesions were selected which were, on 
average, 12  years younger than the available controls. 
HSP16.2 (also known as HSPC034, IFT25, PP25 and 
C1orf41) has debatably been proposed as the eleventh 
member of the HSPB family (HSPB11) [42]. Although 
HSP16.2 functions as a chaperone protein and has anti-
apoptotic properties [42], it does not contain an α-crystallin 
domain, which is highly conserved in HSPB1-10, indicating 
that these proteins are evolutionarily unrelated [43], thus 
possibly explaining our deviant results for HSP16.2. 
Although HSP16.2 is known to be involved in hedgehog 
signalling [44], can partially supress amyloid toxicity in 
a Caenorhabditis elegans model of Alzheimer’s disease [45] 
and is associated with histological tumour grade in malig-
nant brain tumours [46], its exact function in (spinal 
cord) neurones remains to be determined.
In the spinal cord, we show that HSPB5 (αB-crystallin) 
is increased in active inflammatory lesions, while it is 
virtually absent in inactive lesions in the spinal cord. 
This is in contrast to a previous report showing that 
HSPB5 is up-regulated in ~45% of astrocytes in early 
active, late active and inactive brain lesions [25]. Although 
these differences could be due to staining techniques, the 
differential expression of HSPB5 possibly indicates differ-
ences in spinal cord astrocyte responses to demyelination. 
In support of this, an identical mechanical insult induces 
similar levels of astrocyte reactivity in the brain and spinal 
cord, as measured by increased GFAP staining intensity, 
but in the spinal cord the astrocyte response develops 
more rapidly and declines earlier compared to the brain 
[20]. Furthermore, a comparison of astrocyte responses 
in brain and spinal cord upon lysolecithin-induced demy-
elination revealed that 14  days post-injection GFAP reac-
tivity is markedly higher in the spinal cord compared to 
brain [30].
By acting as an extracellular signal to cells, HSPB are 
reported to induce innate immune responses. In MS, 
elevated expression of HSPB5 in MS may influence inflam-
mation, as HSPB5 activates microglia via Toll-like receptor 
(TLR)-2 and CD14 [47,48]. Other HSPBs, e.g. HSPB1 
and HSPB8, have also been reported to act as agonists 
of TLR signalling [49‒51], and thus expression of HSPBs 
are likely to influence inflammatory responses in the CNS. 
Thus the differential expression of HSPB and HSP16.2 
in the CNS may well influence the pathology and clinical 
outcome in MS.
In inflammatory spinal cord lesions, stellate astrocytes 
express HSPB5 ser59 prominently, while hypertrophic 
astrocytes express HSPB5 ser19 and, to a lesser extent, 
HSPB5 ser45. HSPB5 is involved in a multitude of cel-
lular processes by interacting with more than 90 different 
proteins, necessitating mechanisms to post-translationally 
regulate HSPB5 activity, such as phosphorylation [52,53]. 
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HSPB5 can be phosphorylated at three different serine 
residues (ser19, ser45 and ser59). Although the different 
phosphorylated forms show functional overlap, HSPB5 
phosphorylation at ser19 and ser45 is especially important 
in cell cycle regulation, while ser59 is involved mainly 
in inflammatory pathways [26,53]. Recently, phosphoryla-
tion of HSPB5 at ser59 has been implicated in astrogliosis 
[26]. In active brain MS lesions expression of HSPB5 
ser59, but not HSPB5 ser45, is increased in reactive astro-
cytes [26], unlike in the spinal cord, illustrating hetero-
geneity in astrocyte populations and astrocyte responses 
to demyelinating injury across the CNS.
To date, limited data are available on the expression 
profiles of HSPs during (spinal cord) lesion development 
in MS lesions, even though such profiles may hold impor-
tant clues to molecular factors involved in the disease 
process. High levels of HSPB expression in the spinal 
cord and differential expression of (small) HSPs by astro-
cytes and neurones in spinal cord lesions illustrate dif-
ferences between brain and spinal cord in normal 
conditions and upon demyelination. As regional hetero-
geneity probably influences the pathology of MS lesions 
as well as local effectiveness of pharmacological agents, 
research elucidating differences between brain and spinal 
cord may ultimately help to increase the effectiveness of 
(current) therapies on the debilitating spinal cord lesions.
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Supporting Information
Additional supporting information may be found in the 
online version of this article at the publisher’s web site:
Fig. S1. HSP levels in controls and MS patients. HSPB1, 
HSPB5, HSPB6, HSPB8 and HSP16.2 protein levels in 
brain WM/GM and spinal cord WM/GM of controls 
(n  =  8) and MS patients (n  =  8) were determined using 
Western blotting and quantified with Scion Image. Actin 
was used as a loading control. Values are normalized to 
a reference sample. (a) Quantification HSPB1 protein levels 
in controls and MS patients. (b) Quantification HSPB6 
protein levels in controls and MS patients. (c) 
Quantification HSPB8 protein levels in controls and MS 
patients. (d) Quantification HSPB5 protein levels in con-
trols and MS patients.  (e) Quantification HSP16.2 protein 
levels in controls and MS patients. To compare HSP levels 
between MS patients and controls, WM and GM and 
brain and spinal cord, anova or Kruskal–Wallis test and 
post-hoc testing with Sidak’s or Dunn’s multiple compari-
sons test was performed. Data are presented as mean 
with standard error of the mean. Significant data are 
presented (****P  <  0·0001, ***P  <  0·001, **P  <  0·01, 
*P  <  0·05).
Fig. S2. HSP16.2 expression in brain and spinal cord. 
HSP16.2 protein levels in brain WM/GM and spinal cord 
(SPC) WM/GM of controls (n  =  8) and MS patients 
(n  =  8) were determined using Western blotting. A rep-
resentative blot with two controls and one MS patient is 
shown. The reference sample (control spinal cord WM) 
is annotated with an X. Bands are visible at approximately 
16, 40, 60, 70 and 250 kDa.   
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run("Colour Deconvolution", "vectors  =  [User values] 
[r1]  =  0.34028333 [g1]  =  0.5633901 [b1]  =  0.7528604 
[r2]  =  0.25282693 [g2]  =  0.78388995 [b2]  =  0.56709355 
[r3]  =  0.6048769 [g3]  =  0.560661 [b3]  =  0.56549376");
selectWindow(imageTitle+ "-(Colour_1)");
//run("Threshold...");
setThreshold(0,);
run("Measure");
}
